The FDA's inconsistency and the growing gap between its guidance and actions have made regulatory risk a primary evaluation factor for investors, complicating trial design, causing delays, and raising the cost of capital for biotechs.
Some investors view the FDA's current unpredictability as fully reflected in biotech valuations. This contrarian stance means that any stabilization or improvement from the agency represents significant investment upside, as the worst is already assumed.
An unusual alliance of investors, patient advocacy groups, and biotech executives has formed to lobby Washington about the FDA. This broad-based pushback indicates that the agency's problems are perceived as systemic, not just isolated incidents.
A healthy biotech IPO market won't reappear independently. It requires a robust M&A landscape first, which attracts generalist investors back to the sector and provides the necessary market liquidity to successfully support new public offerings.
High 2025 drug approval numbers are a deceptive metric, likely reflecting the operational momentum of a prior, more functional FDA. The true impact of current talent attrition and disruption will likely only surface in 2026 approval statistics.
Moving first-in-human studies to countries like Australia and China is now a core business strategy, not just a cost-saving measure. It allows U.S. biotechs to navigate a more flexible regulatory environment and accelerate development timelines.
Previously considered a capital-efficient area due to regulatory flexibility, the rare disease and gene therapy space is now perceived as high-risk. The FDA is applying greater scrutiny and tightening standards, making development more unpredictable for sponsors.